CA2381699A1 - Novel methods of diagnosis of angiogenesis compostions and methods of screening for angiogenesis modulators - Google Patents
Novel methods of diagnosis of angiogenesis compostions and methods of screening for angiogenesis modulators Download PDFInfo
- Publication number
- CA2381699A1 CA2381699A1 CA002381699A CA2381699A CA2381699A1 CA 2381699 A1 CA2381699 A1 CA 2381699A1 CA 002381699 A CA002381699 A CA 002381699A CA 2381699 A CA2381699 A CA 2381699A CA 2381699 A1 CA2381699 A1 CA 2381699A1
- Authority
- CA
- Canada
- Prior art keywords
- ests
- angiogenesis
- protein
- nucleic acid
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5064—Endothelial cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2550/00—Electrophoretic profiling, e.g. for proteome analysis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Physiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14842599P | 1999-08-11 | 1999-08-11 | |
US60/148,425 | 1999-08-11 | ||
PCT/US2000/022061 WO2001011086A2 (en) | 1999-08-11 | 2000-08-11 | Methods of screening for angiogenesis modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2381699A1 true CA2381699A1 (en) | 2001-02-15 |
Family
ID=22525710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002381699A Abandoned CA2381699A1 (en) | 1999-08-11 | 2000-08-11 | Novel methods of diagnosis of angiogenesis compostions and methods of screening for angiogenesis modulators |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1204764A2 (es) |
JP (1) | JP2003517816A (es) |
AU (1) | AU6902200A (es) |
CA (1) | CA2381699A1 (es) |
MX (1) | MXPA02001439A (es) |
WO (1) | WO2001011086A2 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7803765B2 (en) | 1999-05-05 | 2010-09-28 | Phylogica Limited | Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom |
US7034132B2 (en) | 2001-06-04 | 2006-04-25 | Anderson David W | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
GB0002201D0 (en) * | 2000-01-31 | 2000-03-22 | Imperial College | Process |
US6855690B2 (en) | 2000-06-01 | 2005-02-15 | Children's Medical Center Corporation | Methods and compositions for treating ocular disorders |
JP4393098B2 (ja) | 2002-06-21 | 2010-01-06 | 独立行政法人科学技術振興機構 | アンサマイシン系抗生物質の新規用途及び新規血管新生抑制物質のスクリーニング方法 |
JP2008001720A (ja) * | 2002-06-21 | 2008-01-10 | Japan Science & Technology Agency | アンサマイシン系抗生物質の新規用途及び新規血管新生抑制物質のスクリーニング方法 |
US7276589B2 (en) | 2002-11-26 | 2007-10-02 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
US7285268B2 (en) | 2002-11-26 | 2007-10-23 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
US7485297B2 (en) | 2003-08-12 | 2009-02-03 | Dyax Corp. | Method of inhibition of vascular development using an antibody |
US7871610B2 (en) | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
US7527936B2 (en) | 2004-01-13 | 2009-05-05 | Rigel Pharmaceuticals Inc. | Modulators of angiogenesis |
EP1755659B1 (en) | 2004-03-24 | 2011-11-02 | Abbott Biotherapeutics Corp. | Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation |
CA2568644C (en) | 2004-06-03 | 2015-11-24 | Phylogica Limited | Peptide modulators of cellular phenotype and bi-nucleic acid fragment library |
DK1987178T3 (en) | 2006-02-20 | 2015-04-20 | Phylogica Ltd | Process for the construction and screening of peptide structure libraries |
MY159375A (en) | 2006-03-21 | 2016-12-30 | Genentech Inc | Combinatorial therapy |
CA2663545A1 (en) | 2006-09-19 | 2008-03-27 | Phylogica Limited | Neuroprotective peptide inhibitors of ap-1 signaling and uses thereof |
WO2008154700A1 (en) | 2007-06-20 | 2008-12-24 | Phylogica Limited | Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith |
US7973138B2 (en) | 2007-09-26 | 2011-07-05 | Genentech, Inc. | Antibodies |
EP2411411B1 (en) | 2009-03-25 | 2016-08-31 | F.Hoffmann-La Roche Ag | Novel anti-alpha5beta1 antibodies and uses thereof |
NZ611428A (en) | 2010-12-08 | 2015-07-31 | Stemcentrx Inc | Novel modulators and methods of use |
JP2012125194A (ja) * | 2010-12-16 | 2012-07-05 | Mie Univ | 腫瘍血管新生制御遺伝子 |
PE20161413A1 (es) | 2013-11-04 | 2017-01-10 | Stemcentrx Inc | Conjugados de anticuerpo anti-efna4-farmaco |
WO2017173327A1 (en) * | 2016-03-31 | 2017-10-05 | The Schepens Eye Research Institute, Inc. | Endomucin inhibitor as an anti-angiogenic agent |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1701814A (zh) * | 1992-11-13 | 2005-11-30 | 马克斯普朗克科学促进协会 | 作为血管内皮生长因子受体的f1k-1 |
AU2066797A (en) * | 1996-03-21 | 1997-10-10 | Sugen, Inc. | Assays for kdr/flk-1 receptor tyrosine kinase inhibitors |
JP4121155B2 (ja) * | 1996-12-27 | 2008-07-23 | 中外製薬株式会社 | 新規なセリン/スレオニンキナーゼ遺伝子 |
WO1998051326A1 (en) * | 1997-05-16 | 1998-11-19 | Hsc Research And Development Limited Partnership | Inhibition of angiogenesis by verotoxins |
WO1999011794A2 (en) * | 1997-09-04 | 1999-03-11 | Incyte Pharmaceuticals, Inc. | New vrk1 kinase |
JP2001518318A (ja) * | 1997-10-02 | 2001-10-16 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | Lerk−2媒介細胞接着の調節 |
WO1999038998A1 (en) * | 1998-01-29 | 1999-08-05 | Merck & Co., Inc. | Methods of identifying modulators of kinases responsive to stress |
-
2000
- 2000-08-11 AU AU69022/00A patent/AU6902200A/en not_active Abandoned
- 2000-08-11 MX MXPA02001439A patent/MXPA02001439A/es unknown
- 2000-08-11 JP JP2001515333A patent/JP2003517816A/ja not_active Withdrawn
- 2000-08-11 EP EP00957393A patent/EP1204764A2/en not_active Withdrawn
- 2000-08-11 WO PCT/US2000/022061 patent/WO2001011086A2/en not_active Application Discontinuation
- 2000-08-11 CA CA002381699A patent/CA2381699A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MXPA02001439A (es) | 2002-08-30 |
WO2001011086A9 (en) | 2002-07-11 |
EP1204764A2 (en) | 2002-05-15 |
JP2003517816A (ja) | 2003-06-03 |
WO2001011086A2 (en) | 2001-02-15 |
AU6902200A (en) | 2001-03-05 |
WO2001011086A3 (en) | 2002-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7736853B2 (en) | Methods of diagnosis of androgen-dependent prostate cancer, prostate cancer undergoing androgen withdrawal, and androgen-independent prostate cancer | |
CA2381699A1 (en) | Novel methods of diagnosis of angiogenesis compostions and methods of screening for angiogenesis modulators | |
US6682890B2 (en) | Methods of diagnosing and determining prognosis of colorectal cancer | |
US20030235820A1 (en) | Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer | |
CA2438030A1 (en) | Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators | |
CA2453098A1 (en) | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer | |
US6762020B1 (en) | Methods of diagnosing breast cancer | |
US6750013B2 (en) | Methods for detection and diagnosing of breast cancer | |
CA2451465A1 (en) | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer | |
WO2000055633A9 (en) | Methods of screening for colorectal cancer modulators | |
US6455668B1 (en) | Methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators | |
US20030077590A1 (en) | Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin | |
US20020068036A1 (en) | Novel methods of diagnosis of prostate cancer and/or breast cancer, compositions, and methods of screening for prostate cancer and /or breast cancer modulators | |
US20030108926A1 (en) | Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators | |
US6649342B1 (en) | Methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators | |
US20020076707A1 (en) | Novel methods of diagnosing cancer, compositions, and methods of screening for cancer modulators | |
US6566502B1 (en) | Methods of diagnosing cancer, compositions, and methods of screening for cancer modulators | |
US20030157544A1 (en) | Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators | |
WO2002016939A2 (en) | Methods of diagnosis of cancer and screening for cancer modulators | |
US20030044803A1 (en) | Methods for diagnosis and treatment of diseases associated with altered expression of JAK1 | |
US20030198951A1 (en) | Novel methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators | |
EP1410035A2 (en) | Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators | |
WO2003027321A2 (en) | Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin | |
US20020102544A1 (en) | Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators | |
WO2002021134A2 (en) | Methods of diagnosing breast cancer and screening for modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |